Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA, which is a subgroup of hereditary ataxia, HD, which is a neurodegenerative disorder, and RTT, a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it.